CompletedEUCTR 2006-001618-34
An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression
This historical record does not confirm current site availability.
Historical research recordFrance + Italy
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- France · Italy
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 410
- Sponsor
- BOEHRINGER ING.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Italy
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-001618-34
- Official title
Show the full official title
An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedFrance · Italy
Questions about this study
Who is behind this study?
The study sponsor is BOEHRINGER ING.
Want to explore more studies?
Explore studiesRelated studies
Intranasal Esketamine Added to Standard Care for Adults at Imminent Suicide Risk
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression